Details

Autor(en) / Beteiligte

• Kim, Sarah
• Scanga, Charles A.
• Miranda Silva, Carolina de
• Zimmerman, Matthew
• Causgrove, Chelsea
• Stein, Brianne
• Dartois, Véronique
• Peloquin, Charles A.
• Graham, Emily
• Louie, Arnold
• Flynn, JoAnne L.
• Schmidt, Stephan
• Drusano, George L.

Titel

Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates

Ist Teil von

• European journal of pharmaceutical sciences, 2020-08, Vol.151, p.105421, Article 105421

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Non-human primates (NHP) are thought to be a good preclinical animal model for tuberculosis because they develop disease characteristics that are similar to humans. The objective of the current study was to determine if NHPs can also be used to reliably predict the exposure of tedizolid, sutezolid, and its biologically active metabolite sutezolid-M1 in humans. The prodrug tedizolid phosphate and sutezolid were administered orally to NHPs either once or twice daily for up to eight days. The active moieties, tedizolid, and sutezolid showed linear pharmacokinetics and respective concentration-time profiles could be described by one-compartment body models with first-order elimination. One additional metabolite compartment with first-order elimination was found appropriate to capture the pharmacokinetics of sutezolid-M1. Once allometrically scaled to humans with a fixed exponent of 0.75 for apparent clearance and 1 for apparent volume of distribution, the AUCs of tedizolid and sutezolid were predicted reasonably well, whereas Cmax was under-predicted for sutezolid. Both NHP and humanized concentration-time profiles will now be used in vitro hollow-fiber pharmacodynamic experiments to determine if differences in drug exposures result in differences in Mycobacterium tuberculosis kill and emergence of resistance. [Display omitted]